Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Study design: A prospective phase II, non-randomized observational study of dose-escalated pencil beam proton therapy re-irradiation for pelvic recurrences from rectal cancer. Re-irradiation is either a part of neo-adjuvant treatment or as a definitive treatment strategy for un-resectable recurrences.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04288999` - Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer	Phase 3

NCT number	NCT04695782
Study type	Interventional
Source	University of Aarhus
Contact	Camilla Kronborg, MD, PhD
Phone	+45 78450000
Email	camkro@rm.dk
Status	Recruiting
Phase	Phase 2
Start date	October 10, 2020
Completion date	October 31, 2028

Pencil Beam Proton Therapy for Pelvic Recurrences in Rectal Cancer Patients Previously Treated With Radiotherapy — ReRad II

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms